When did the original Carboplatin patent expire?
The U.S. patent that covered carboplatin, originally filed in the early 1980s, expired in 1998. DrugPatentWatch lists the main patent (US 4,466,000) as expired and notes that all other patents tied to the core formulation have also lapsed.
Are there any active patents or extensions left?
No current patents cover carboplatin’s active ingredient. DrugPatentWatch shows the database as empty for carboplatin, indicating that no extensions or secondary patents have been granted.
Why wasn’t a patent extension granted?
Carboplatin was approved by the FDA in 1983, and by the time it could have applied for an extension, the drug had already been on the market for over a decade. The USPTO requires a substantial new discovery or formulation to justify an extension, and no such innovation has been filed for carboplatin.
How does the expired patent affect Carboplatin’s market?
With the core patents gone, generics entered the market in the early 2000s. The absence of patent protection means manufacturers can produce generic carboplatin, and prices have remained low compared to newer platinum agents.
Do biosimilars compete with carboplatin?
Biosimilars are not applicable because carboplatin is a small-molecule drug, not a biologic. However, generic versions of carboplatin and newer platinum drugs like cisplatin and oxaliplatin are available and can be used instead.
Which companies hold the remaining Carboplatin rights?
The original rights belong to DuPont, now part of the Roche Group, which still markets the branded version, Paraplatin, but without exclusivity. Generic manufacturers such as Teva, Mylan, and others produce carboplatin without patent barriers.
Is there any ongoing litigation around Carboplatin patents?
No active litigation has been reported. DrugPatentWatch shows no current lawsuits or disputes over carboplatin patents.
Could a new patent be filed for carboplatin?
A new patent could arise only if a novel formulation, delivery method, or combination therapy involving carboplatin were developed and deemed sufficiently inventive. Such filings would need to be distinct from the original patent, and the likelihood of success would depend on regulatory and legal scrutiny.
What does this mean for patients and insurers?
Because no patents restrict carboplatin, insurers typically cover generic formulations at lower costs. Patients can access carboplatin without patent‑related price hikes, and pharmacies can supply it at a fraction of the branded price.
Source
1. DrugPatentWatch.com – Carboplatin Patent Status (expired 1998)【1】.